The prognostic role of serum albumin in patients receiving induction chemotherapy for acute myeloid leukemia (AML).
Hossein Sadrzadeh(Boston University), Amir T. Fathi(University of Southern California), Philip C. Amrein(Massachusetts General Hospital), Andrew M. Brunner(Harvard University), Yi-Bin Albert Chen(Harvard University), Lillian Werner(Dana-Farber Cancer Institute), Thomas R. Spitzer(Harvard University), Karen K. Ballen(University of Virginia Health System), Benjamin J. Drapkin(Southwestern Medical Center), Eyal C. Attar(Memorial Sloan Kettering Cancer Center), Donna Neuberg(Otsuka (Japan)), Steven L. McAfee(Harvard University), Loren Babirak(Harvard University)
Cited by 2
Related Papers
Analysis of <i>Fusobacterium</i> persistence and antibiotic response in colorectal cancer
|Science|2017|1.6k
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
|Nature|2018|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k